Cancerrop was founded in 2001 and established the research institute in 2007. We obtained the genetic testing agency certification in 2008 and were listed on KOSDAQ(Korean stock market) in 2015. In 2017, we changed the company name from MGMed to Cancerrop. We are a biotech company that has developed and manufactured the latest molecular diagnostic method that can diagnose genetic diseases occurring throughout our whole life. Recently, we are focusing on penetrating the global markets with the COVID-19 Detection Kit.

[ Q-Sens® COVID-19 Detection Kit V2 ]

The Q-Sens® COVID-19 Detection Kit V2 uses real-time reverse transcription-polymerase chain reaction(RT-PCR) technology. It can be easily performed by one step of adding of RNA template to the primer/probe mixture. Q-Sens® Kit V2 had already acquired the official approvals from MFDS in Korea and the CE-IVD.

Features and Advantages:

•One-Tube, One-Step RT-PCR

•Compatible instruments: CFX96, ABI 7500 with viewer software program

•Specimens: Upper respiratory (Nasopharyngeal swab, Oropharyngeal swab), Lower respiratory (Sputum)

•Target gene: RdRp gene, E gene

•TAT (Real-Time PCR): within 2 hours

•1kit/100tests

[ Q-Sens® COVID-19 IgG/IgM Rapid Kit ]

The Q-Sens® COVID-19 IgG/IgM Rapid Kit was developed as an immunochromatographic assay to assist diagnosis of disease and immunological conditions by detecting anti-SARS-CoV-2 IgG and IgM antibodies in specimens(fingerstick whole blood, venous whole blood, serum, and plasma). It was developed according to the guidelines of WHO and KCDC.

Features and Advantages:

•Quick and easy testing in 10 minutes

•No additional instruments required

•Sensitivity/Specificity: 94% / 96%

•Storage temperature: 20℃ ~ 30℃

•1kit/100tests

View brochure